Hereditary Oncology Testing: Wei Shen, Ph.D.
from Answers from the Lab Hosted by Mayo Clinic Laboratories
(00:32): But before we get started, Dr. Shen, could you provide us with a little bit about you and your background? (01:15): So why don't we start our discussion today with having you give us a brief overview of these new hereditary oncology panels. (03:56): Can you tell us which patients should have this type of testing and when it should be performed? (05:31): Do you want to talk about what other test options are available and how our testing is different or how it compares to this other testing? (06:51): So then the last question I have for you today, and maybe the most important is how are these results used in patient care?
Embed this episode
What this episode covers
Wei Shen, Ph.D., discusses Mayo Clinic Laboratories’ new hereditary oncology panels, which use next-generation sequencing to identify germline alterations associated with increased cancer risk. Curated through a rigorous selection framework developed by Mayo Clinic oncology experts, the panels include only clinically significant genes to provide clarity on diagnosis, prognosis, and treatment approaches for individuals at risk for hereditary cancers.
No transcript yet.